Immupharma Share Discussion Threads

[coppers] 29/9/2021 09:21

I think this says it all!

Administrative expenses were GBP1.5 million during the Period (GBP1.0 million for the six months ended 30 June 2020), with the increase being largely due to departure costs regarding Directors and Related Parties in the period, which were settled post-period-end.

[1bond] 29/9/2021 08:24

I thought it was a very useful update. The company has already said 8-12 weeks for news on the PK study, so be patient.

[nobbygnome] 29/9/2021 07:51

Uh oh, quite a few warning signals in that corporate update. Barge poles come to mind.....how can the PK study not have started yet!

[david gruen] 29/9/2021 07:48

Financial Review

ImmuPharma's cash balance at 30 June 2021 was GBP4.2 million (GBP5.9 million at 31 December 2020, GBP2.7 million at 30 June 2020). Financial asset related to investment in Incanthera plc amounted to GBP1.2 million (GBP1.8 million at 31 December 2020, GBP1.2 million at 30 June 2020) and warrants granted has resulted in amount of GBP0.2 million (GBP0.6 million at 31 December 2020 and GBP0.5 million at 30 June 2020), recognized under financial asset. As a result of the Lanstead Sharing Agreements, the Company had a derivative financial asset of GBP0.2 million at 30 June 2021 (GBP1.2 million at 31 December 2020, GBP2.5 million at 30 June 2020). The convertible loans liability amounted to GBP0.7 million (GBP0.6 million at 31 December 2020, GBP1.8 million at 30 June 2020). Trade and other payables liability amounted to GBP1.1 million at 30 June 2021 (GBP0.6 million at 31 December 2020, GBP0.2 million at 30 June 2020). The increase was mainly caused by Directors and Related Party departures. Basic and diluted loss per share were 1.46p and 1.46p respectively (30 June 2020: 1.69p and 1.69p). In line with the Company's current policy, no interim dividend is proposed.

Operating loss for the Period was GBP3.1 million (GBP2.9 million for the six months ended 30 June 2020). Research and development expenditure in the Period was GBP1.3 million (GBP0.9 million for the six months ended 30 June 2020). Administrative expenses were GBP1.5 million during the Period (GBP1.0 million for the six months ended 30 June 2020), with the increase being largely due to departure costs regarding Directors and Related Parties in the period, which were settled post period-end. The share based expense was GBP0.3 million (GBP1.0 million for the six months ended 30 June 2020). Finance costs for the Period were GBP0.9 million (GBP0.4 million for the six months ended 30 June 2020). This arose largely due to the calculation of fair value of the derivative financial asset - "Lanstead Sharing Agreements", which resulted in a finance loss of GBP0.8 million. Finance income for the Period was GBP0.1 million (GBP0.1 million for the six months ended 30 June 2020). It primarily arose due to foreign exchange gain in relation to intercompany receivables.

Given the stage of ImmuPharma's development, the fact that losses have continued to be made is to be expected since there is minimal revenue and business activity is concerned with significant investment in the form of clinical development expenditure, in addition to maintaining the infrastructure of the Company.

Current Activities and Outlook

The last few months have seen significant changes in the leadership of the Company. We have created positive and constructive changes within the business, with a focus on delivery of product development, value added milestones and a much more commercially focussed corporate strategy. The new Board, together with the excellent team supporting us, are determined to progress the development and commercialisation of all the key assets in our portfolio and to build shareholder value.

In closing, the Board would like to take this opportunity to thank its shareholders, new and longstanding, for their patience and support as well as its staff, corporate and scientific advisers and our partners including, CNRS and Avion.

[best1467] 29/9/2021 07:13

PK Study still not started when you think it’s only Enrolling 24 healthy males it’s disappointing.Nice to see the cash burn been reduced at last after the latest about turn on dual listing

[lord loads of lolly] 23/9/2021 09:05

I presume you're referring to Morrisons again?

[the stinger] 20/9/2021 10:04

I’m impressed with the news flow, must say. Very good BOD

[lord loads of lolly] 11/9/2021 20:10

the stinger - you’re right, except that it’s Morrisons. Easy mistake. The two sound very similar.

[the stinger] 07/9/2021 11:08

Take over news on route.

[replicas1967] 05/9/2021 20:01

I’m with you Nobby 🙄

[nobbygnome] 05/9/2021 17:28

I'm going to buy now because stinger says so! He is the guru....

Sometimes on these boards I lose the will to live.....

[the stinger] 05/9/2021 17:24

A 20m market cap is very cheap here. Potential to 3 bag!.

[the stinger] 05/9/2021 17:23

My source tell me big news coming!!

[the stinger] 05/9/2021 15:59

Long now... news soon which will change sentiment !

[1ultimate] 04/9/2021 19:11

Lol 😂 the idiot edited his post from earlier hilarious 😂😂

[brad44] 04/9/2021 16:18

Hilarious! Did you forget if you were long or short!

[the stinger] 04/9/2021 12:16

News soon hopefully.

[the stinger] 30/8/2021 12:37

Looks cheap this SP?, Plenty of products being worked on.

[nobbygnome] 30/8/2021 12:13

Is that what the company told you or are you just guessing? And could you tell me why 'the way the drug is administered' is relevant?

[marketgem] 25/8/2021 11:30

If I've understood it wasn't a requirement in the first study but as time goes on so does best practice and standards, due to the way the drug is administered this is some data that's now required. Seems like a box ticking exercise

[nobbygnome] 24/8/2021 21:49

But why do the FDA want the PK study done. I am all ears as I would love to know. The company so far has omitted to tell us....

[marketgem] 24/8/2021 21:10

The director buying is not massive but not insignificant either, just looking at recent director purchases not many higher than Tim's but would be nice if he bought a few more.https://www.sharesmagazine.co.uk/director-deals/latest-deals?page=3You have to understand that Tim has only just taken control so he needs a chance and already he's naming changes. Tim is in France this week progressing the drug pipeline and making deals which we know he is capable of. Avion are funding the phase 3 of Lupuzor, despite the trolling there not going to fund something they think will fail. Tim has said on record the PK study is just a formality, he just needs to supply the fda with some data but the trial will go ahead. Lots to look forward to.